In contrast, the targeted therapy doublet sensitised tumours to anti-PD-1, leading to significantly prolonged survival, consistent with our previous observations in subcutaneous tumours (Figs. 4c, 7b and Supplementary Fig. 4b). This evidence concerns the gene PDCD1 and neoplasm.